1. Ho PR et al. Lancet Neurol. 2017;16:925-933; 2. Physician information and management guidelines for patients with multiple sclerosis receiving TYSABRI (IV & SC) therapy (Version 23). October 2025. 3. Kappos L et al. Lancet Neurol. 2011;10:745-758; 4. TYSABRI (natalizumab). [summary of product characteristics].
Monitoring & Follow up
FOR HEALTHCARE PROFESSIONALS ONLY
The site you are about to enter is intended for healthcare professionals.
Please confirm that you are a healthcare professional.
